Research
Hormonal
Obesity pathophysiology is driven by complex interactions between genetic susceptibility, environmental factors, and hormonal signaling (leptin, insulin, ghrelin, GLP-1) that regulate energy balance, rather than simple caloric imbalance alone.
Obesity is not just a failure of willpower; it involves complex hormonal signals (like leptin and insulin) and genetics. Effective management often requires addressing these biological drivers, potentially through lifestyle changes combined with medical therapies that target these specific pathways.
GoodQualifiesHIGH confidence
There is an intricate interplay between genetic, environmental, and psychosocial factors which mediate food intake and energy expenditure [30].
Why this rating
Review of multiple studies and established physiological mechanisms.
Source
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Erind Gjermeni · MDPI (MDPI AG) · 2021
DOI 10.3390/biom11101426
narrative_reviewCited 94×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists and related incretin-based therapies are effective pharmacological interventions for obesity and type 2 diabetes, offering superior weight loss and cardiovascular benefits compared to previous treatments.Strong
- Brown adipose tissue (BAT) activation and 'browning' of white adipose tissue represent a potential therapeutic target for increasing energy expenditure and reducing body weight.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →